Chembio Diagnostics Stock Is Trading Higher On FDA Emergency Use Nod For Its Partner's LumiraDX COVID-19 Antibody Test
- The FDA has granted emergency use authorization to Chembio Diagnostics Inc's (NASDAQ: CEMI) partner LumiraDx's COVID-19 antibody test.
- LumiraDx and Chembio had announced a partnership on March 12, 2020 to develop point of care COVID-19 antibody test.
- The nod comes for LumiraDx SARS-CoV-2 Ab Test, a microfluidic immunofluorescence assay for the qualitative detection of total antibodies in whole human blood, plasma, or serum for indication of recent or prior infection.
- Recently, the Company received a $28 million order to supply DPP SARS-CoV-2 Antigen tests for delivery during 2021 in Brazil.
- Price Action: CEMI shares are up 15.1% at $3.39 during the market session on the last check Tuesday.
- Related content: Benzinga's Full FDA Calendar.
- Editor's note: The item has been updated to include the partnership details of Chembio and LumiraDx in the second bullet
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Posted-In: Long Ideas News Penny Stocks Health Care FDA Movers Trading Ideas General
